18+ Years
This is a 34-week Phase 2 study testing the safety, effectiveness, and other properties of an investigational product in people with moderate to severe ulcerative colitis.
This 52-week study evaluates the safety and effectiveness of an investigational product in patients with moderate to severe ulcerative colitis.